Skip to main content

Table 4 Correlation of GPC3 expression with the clinical phenotypes of lung squamous cell carcinoma (LUSC) samples

From: GPC3 affects the prognosis of lung adenocarcinoma and lung squamous cell carcinoma

Characteristics Variable Number of patients GPC3 expression Test P value
High Percent (%) Low Percent (%)
Age ≥ 65 355 183 64.9 172 66.4 Wilcoxon 0.9002
  < 65 186 99 35.1 87 33.6   
Location Central Lung 157 83 57.2 74 65.5 Wilcoxon 0.3471
  Peripheral Lung 101 62 42.8 39 34.5   
years_smoked ≥ 53 177 146 59.1 141 65 Wilcoxon 0.2589
  < 53 287 101 40.9 76 35   
pathologic_M M0 443 0 0 1 0.4 Kruskal 0.5125
  M1 6 0 0 1 0.4   
  M1a 1 1 0.3 5 1.9   
  M1b 1 235 82.2 208 80.3   
  MX 94 50 17.5 44 17   
pathologic_N N0 352 1 0.3 6 2.3 Kruskal 0.4514
  N1 143 189 65.4 163 62.5   
  N2 43 73 25.3 70 26.8   
  N3 5 22 7.6 21 8   
  NX 7 4 1.4 1 0.4   
pathologic_T T1 53 15 5.2 11 4.2 Kruskal 0.1308
  T1a 26 20 6.9 24 9.2   
  T1b 44 59 20.4 41 15.7   
  T2 187 14 4.8 10 3.8   
  T2a 100 26 9 14 5.4   
  T2b 40 96 33.2 91 34.9   
  T3 76 34 11.8 42 16.1   
  T4 24 25 8.7 28 10.7   
Radiation therapy Yes 51 24 10.4 27 13.1 Wilcoxon 0.2045
  No 386 207 89.6 179 86.9   
Gender Female 144 216 74.7 190 72.8 Wilcoxon 0.4309
  Male 406 73 25.3 71 27.2   
Tumor stage I 270 144 50.2 126 48.6 Kruskal 0.3464
  II 179 1 0.3 7 2.7   
  III 89 94 32.8 85 32.8   
  IV 8 48 16.7 41 15.8